LLY Stock Recent News

Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world comparison of overweight and obese patients with cardiovascular disease but not diabetes.

Although the stock has experienced its fair share of turbulence in 2025, Eli Lilly LLY is rapidly emerging as a key consideration for investors seeking to hedge their portfolios away from tech and AI picks.

Eli Lilly has partnered with a leading Chinese tech company, JD Health to fast-track its presence in China's rapidly expanding obesity drug market, boosting the company's global growth in the weight-loss sector. Eli Lilly's move into the obesity drug market is reshaping the global pharma landscape.

Trading is quiet in Eli Lilly and Co  LLY on Thursday. The stock has stalled out at a resistance level.

Eli Lilly and Company's orforglipron shows strong efficacy and manufacturing advantages over Novo Nordisk's oral semaglutide, supporting future growth in the obesity and diabetes market. Orforglipron's convenience, scalability, and potential dual-indication label position it as a key driver for Eli Lilly's revenue diversification and premium valuation. Despite payer coverage and tolerability challenges, the massive eligible population and orforglipron's advantages should drive exponential sales growth.

In 2018, Apple became the first publicly traded company to reach a $1 trillion market capitalization. Several more have joined that club since, but it remains highly exclusive, with fewer than 10 members among the thousands of stocks trading on equity markets.

According to a filing with the Securities and Exchange Commission dated Aug. 12, 2025, Stevens Capital Management LP completely exited its position in Eli Lilly and Company (LLY -0.20%), by selling all 12,036 shares in Q2 2025.

Eli Lilly and Co (NYSE:LLY) has halted shipments of its Mounjaro diabetes and weight-loss drug to the UK ahead of a planned price hike next month. Earlier this week the US drug giant warned against "inappropriate stockpiling of medicines", as customers rushed to buy the drug ahead of a planned 170% price rise, where the highest dose of the medicine will increase from £122 to £330.

Eli Lilly has temporarily paused shipments of its weight-loss drug Mounjaro in the UK, ahead of a new price hike for the treatment set to come into effect starting next month.

LLY's obesity pill orforglipron hits weight-loss and A1C goals in a phase III trial, lifting shares nearly 6% and reviving investor confidence.